Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Galanin antagonist effective against depression-like behavior in rats

Feb. 1, 2007

RPI-78M begins phase IIb study in adrenomyeloneuropathy

Jan. 31, 2007

Targeting orexin receptors may be useful to treat sleep disorders

Jan. 31, 2007

New agents for schizophrenia and depression disclosed in recent patents

Jan. 31, 2007

Nasalfent begins phase III program in breakthrough cancer pain

Jan. 31, 2007

Recent Allergan and Florida Atlantic University patents divulge novel analgesic agents

Jan. 30, 2007

T-0047 clinical testing resumes

Jan. 30, 2007

Japanese approval for Modiodal in narcolepsy

Jan. 30, 2007

Valeant develops intranasal diazepam for seizure emergencies

Jan. 30, 2007

Michael J. Fox Foundation funds industry development efforts in Parkinson's

Jan. 30, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...